|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Stanford University |
|---|---|
| Information provided by: | Stanford University |
| ClinicalTrials.gov Identifier: | NCT00374621 |
Purpose
The purpose of this study is to determine the efficacy and safety of the addition of intravaginal isosorbide mononitrate to an established protocol of oral misoprostol for cervical ripening and labor induction.
| Condition | Intervention |
|---|---|
|
Cervical Ripening. |
Drug: Misoprostol with or without isosorbide mononitrate |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Randomized Clinical Trial of Cervical Ripening and Labor Induction Using Stepwise Oral Misoprostol With or Without Intravaginal Isosorbide Mononitrate |
| Enrollment: | 156 |
| Study Start Date: | September 2006 |
| Study Completion Date: | January 2010 |
| Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Misoprostol |
Drug: Misoprostol with or without isosorbide mononitrate
Misoprostol 50 micrograms orally then 100 micrograms every 4 hours for up to four doses until modified Bishop score of 8 or higher was observed vs. the same misoprostol dosing plus isosorbide mononitrate 40 mg vaginally every 6 hours up to two doses total until a modified Bishop sore of at least 8 was observed
|
| Active Comparator: Misoprostol with Isosorbide Mononitrate |
Drug: Misoprostol with or without isosorbide mononitrate
Misoprostol 50 micrograms orally then 100 micrograms every 4 hours for up to four doses until modified Bishop score of 8 or higher was observed vs. the same misoprostol dosing plus isosorbide mononitrate 40 mg vaginally every 6 hours up to two doses total until a modified Bishop sore of at least 8 was observed
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria::
Exclusion Criteria:
Contacts and Locations| United States, California | |
| Stanford University School of Medicine | |
| Stanford, California, United States, 94305 | |
| Principal Investigator: | Yasser Yehia El-Sayed | Stanford University |
More Information
| Responsible Party: | Yasser Yehia El-Sayed, Stanford University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT00374621 History of Changes |
| Other Study ID Numbers: | 97274 |
| Study First Received: | September 7, 2006 |
| Last Updated: | June 13, 2011 |
| Health Authority: | United States: Institutional Review Board |
|
Isosorbide Isosorbide-5-mononitrate Isosorbide Dinitrate Misoprostol Diuretics, Osmotic Diuretics Natriuretic Agents Physiological Effects of Drugs Pharmacologic Actions Cardiovascular Agents |
Therapeutic Uses Vasodilator Agents Nitric Oxide Donors Molecular Mechanisms of Pharmacological Action Anti-Ulcer Agents Gastrointestinal Agents Oxytocics Reproductive Control Agents Abortifacient Agents, Nonsteroidal Abortifacient Agents |